M. Principi, M. Barone, M. Pricci, D. Tullio, N. Losurdo et al., Ulcerative colitis: from inflammation to cancer. Do estrogen receptors have a role, World J Gastroenterol, vol.20, pp.11496-11500, 2014.

J. Galon, A. Costes, F. Sanchez-cabo, A. Kirilovsky, B. Mlecnik et al., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, vol.313, pp.1960-64, 2006.

F. Pag-es, A. Berger, M. Camus, F. Sanchez-cabo, A. Costes et al., Effector memory T cells, early metastasis, and survival in colorectal cancer, The N Engl J Med, vol.353, pp.2654-66, 2005.

P. Salama, C. Stewart, C. Forrest, C. Platell, and B. Iacopetta, FOXP3þ cell density in lymphoid follicles from histologically normal mucosa is a strong prognostic factor in early stage colon cancer, Cancer Immunol Immunother, vol.61, pp.1183-90, 2012.

G. Bindea, B. Mlecnik, M. Tosolini, A. Kirilovsky, M. Waldner et al., Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer, Immunity, vol.39, pp.782-95, 2013.

Z. Mei, Y. Liu, C. Liu, A. Cui, Z. Liang et al., Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis, Br J Cancer, vol.110, pp.1595-605, 2014.

P. Salama, M. Phillips, F. Grieu, M. Morris, N. Zeps et al., Tumorinfiltrating FOXP3þ T regulatory cells show strong prognostic significance in colorectal cancer, J Clin Oncol, vol.27, pp.186-92, 2009.

J. Liu, Y. Duan, X. Cheng, X. Chen, W. Xie et al., IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma, Biochem Biophys Res Commun, vol.407, pp.348-54, 2011.

, www.aacrjournals.org Cancer Res, vol.76, issue.18, 2016.

, MDSC and Th17 in FOLFOX-Bevacizumab-Treated mCRC Patients

A. S. Chung, X. Wu, G. Zhuang, H. Ngu, I. Kasman et al., An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy, Nat Med, vol.19, pp.1114-1137, 2013.

L. Apetoh, F. Vegran, S. Ladoire, and F. Ghiringhelli, Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies, Curr Mol Med, vol.11, pp.365-72, 2011.

D. Marvel and D. I. Gabrilovich, Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected, J Clin Invest, vol.125, pp.3356-64, 2015.

D. I. Gabrilovich, S. Ostrand-rosenberg, and V. Bronte, Coordinated regulation of myeloid cells by tumours, Nat Rev Immunol, vol.12, pp.253-68, 2012.

S. Solito, I. Marigo, L. Pinton, V. Damuzzo, and S. Mandruzzato, Myeloidderived suppressor cell heterogeneity in human cancers, Ann N Y Acad Sci, vol.1319, pp.47-65, 2014.

L. Y. Ouyang, X. J. Wu, S. B. Ye, R. X. Zhang, Z. L. Li et al., Tumorinduced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer, J Transl Med, vol.13, p.47, 2015.

J. Vincent, G. Mignot, F. Chalmin, S. Ladoire, M. Bruchard et al., 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity, Cancer Res, vol.70, pp.3052-61, 2010.

M. Bruchard, G. Mignot, V. Derang-ere, F. Chalmin, A. Chevriaux et al., Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth, Nat Med, vol.19, pp.57-64, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00919371

E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, vol.45, pp.228-275, 2009.

N. J. Mccleary, J. A. Meyerhardt, E. Green, G. Yothers, A. De-gramont et al., Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database, J Clin Oncol, vol.31, pp.2600-2606, 2013.

Y. D. Mahnke and M. Roederer, Optimizing a multicolor immunophenotyping assay, Clin Lab Med, vol.27, pp.469-85, 2007.

A. Tesniere, L. Apetoh, F. Ghiringhelli, N. Joza, T. Panaretakis et al., Immunogenic cancer cell death: a key-lock paradigm, Curr Opin Immunol, vol.20, pp.504-515, 2008.

B. Zhang, Z. Wang, L. Wu, M. Zhang, W. Li et al., Circulating and tumorinfiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma, PLoS One, vol.8, p.57114, 2013.

J. Bastid, A. Cottalorda-regairaz, G. Alberici, N. Bonnefoy, and J. F. Eliaou, Bensussan A. ENTPD1/CD39 is a promising therapeutic target in oncology, Oncogene, vol.32, pp.1743-51, 2013.

F. C-h-e-nm, C. Nf, C. , S. , Y. et al., IL-6-stimulated CD11bþ CD14þ HLA-DR-myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus, Oncotarget, vol.5, pp.8716-8744, 2014.

M. Idorn, T. Kollgaard, P. Kongsted, L. Sengelov, T. Straten et al., Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer, Cancer Immunol Immunother, vol.63, pp.1177-87, 2014.

A. Romano, N. L. Parrinello, C. Vetro, S. Forte, A. Chiarenza et al., Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin lymphoma patients treated up-front with a risk-adapted strategy, Br J Haematol, vol.168, pp.689-700, 2015.

J. Kanterman, M. Sade-feldman, M. Biton, E. Ish-shalom, A. Lasry et al., Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes, Cancer Res, vol.74, pp.6022-6057, 2014.

G. L. Stritesky, N. Yeh, and M. Kaplan, IL-23 promotes maintenance but not commitment to the Th17 lineage, Journal of immunology, vol.181, pp.5948-5955, 2008.

C. Dong, TH17 cells in development: an updated view of their molecular identity and genetic programming, Nature reviews. Immunology, vol.8, pp.337-348, 2008.

S. C. Liang, Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides, The Journal of experimental medicine, vol.203, pp.2271-2279, 2006.

M. Ciofani, A validated regulatory network for Th17 cell specification, Cell, vol.151, pp.289-303, 2012.

I. I. Ivanov, The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells, Cell, vol.126, pp.1121-1133, 2006.

F. Martin, L. Apetoh, and F. Ghiringhelli, Controversies on the role of Th17 in cancer: a TGF-betadependent immunosuppressive activity? Trends in molecular medicine, vol.18, pp.742-749, 2012.

J. Liu, IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma, Biochemical and biophysical research communications, vol.407, pp.348-354, 2011.

N. Martin-orozco, T helper 17 cells promote cytotoxic T cell activation in tumor immunity, Immunity, vol.31, pp.787-798, 2009.

M. Numasaki, Interleukin-17 promotes angiogenesis and tumor growth, Blood, vol.101, pp.2620-2627, 2003.

C. Loncle, IL17 Functions through the Novel REG3beta-JAK2-STAT3 Inflammatory Pathway to Promote the Transition from Chronic Pancreatitis to Pancreatic Cancer, Cancer research, vol.75, pp.4852-4862, 2015.

D. He, IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells, Journal of immunology, vol.184, pp.2281-2288, 2010.

L. Wang, IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway, The Journal of experimental medicine, vol.206, pp.1457-1464, 2009.

H. Berger, SOCS3 transactivation by PPARgamma prevents IL-17-driven cancer growth, Cancer research, vol.73, pp.3578-3590, 2013.

Z. Wen, Z. Zhong, J. E. Darnell, and . Jr, Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation, Cell, vol.82, pp.241-250, 1995.

Z. L. Yuan, Y. J. Guan, D. Chatterjee, and Y. E. Chin, Stat3 dimerization regulated by reversible acetylation of a single lysine residue, Science, vol.307, pp.269-273, 2005.

Y. Nie, STAT3 inhibition of gluconeogenesis is downregulated by SirT1, Nature cell biology, vol.11, pp.492-500, 2009.

D. Chauhan, Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells, British journal of haematology, vol.155, pp.588-598, 2011.

K. B. Harikumar, Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer, International journal of cancer. Journal international du cancer, vol.127, pp.257-268, 2010.

C. E. Harper, Resveratrol suppresses prostate cancer progression in transgenic mice, Carcinogenesis, vol.28, pp.1946-1953, 2007.

C. C. Chini, SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway. Clinical cancer research : an official journal of the, 2015.

C. H. Hung, S. H. Chan, P. M. Chu, H. C. Lin, and K. L. Tsai, Metformin regulates oxLDL-facilitated endothelial dysfunction by modulation of SIRT1 through repressing LOX-1-modulated oxidative signaling, Oncotarget, 2016.

P. L. Tyack, J. Calambokidis, A. Friedlaender, J. Goldbogen, B. Southall et al., First Long-Term Behavioral Records from Cuvier's Beaked Whales (Ziphius cavirostris) Reveal Record-Breaking Dives, PLoS ONE, vol.9, issue.3, p.142287, 2014.

E. Zhang, Metformin and Resveratrol Inhibited High Glucose-Induced Metabolic Memory of Endothelial Senescence through SIRT1/p300/p53/p21 Pathway, PloS one, vol.10, p.143814, 2015.

H. W. Lim, SIRT1 deacetylates RORgammat and enhances Th17 cell generation, The Journal of experimental medicine, vol.212, pp.607-617, 2015.

L. Durant, Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis, Immunity, vol.32, pp.605-615, 2010.

F. Ghisays, The N-Terminal Domain of SIRT1 Is a Positive Regulator of Endogenous SIRT1-Dependent Deacetylation and Transcriptional Outputs, Cell reports, 2015.

L. Han, SIRT1 is regulated by a PPAR{gamma}-SIRT1 negative feedback loop associated with senescence, Nucleic acids research, vol.38, pp.7458-7471, 2010.

Q. Ruan and Y. H. Chen, Nuclear factor-kappaB in immunity and inflammation: the Treg and Th17 connection, Advances in experimental medicine and biology, vol.946, pp.207-221, 2012.

S. Zhuang, Regulation of STAT signaling by acetylation, Cellular signalling, vol.25, pp.1924-1931, 2013.

F. Chalmin, Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression, Immunity, vol.36, pp.362-373, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00821485

M. Bruchard, Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth, Nature medicine, vol.19, pp.57-64, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00919371

S. L. Gaffen, An overview of IL-17 function and signaling, Cytokine, vol.43, pp.402-407, 2008.

E. Bettelli, T. Korn, M. Oukka, and V. K. Kuchroo, Induction and effector functions of T(H)17 cells, Nature, vol.453, pp.1051-1057, 2008.

A. Laurence, Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation, Immunity, vol.26, pp.371-381, 2007.

M. Veldhoen, K. Hirota, J. Christensen, A. O'garra, and B. Stockinger, Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells, The Journal of experimental medicine, vol.206, pp.43-49, 2009.

Y. D. Mahnke and M. Roederer, Optimizing a multicolor immunophenotyping assay, Clinics in laboratory medicine, vol.27, pp.469-485, 2007.

M. Thibaudin, Human ectonucleotidase-expressing CD25 Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions, Oncoimmunology, vol.5, p.1055444, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01438254

M. Tosolini, Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer, Cancer research, vol.71, pp.1263-1271, 2011.

J. Zhang, The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice, The Journal of clinical investigation, vol.119, pp.3048-3058, 2009.

T. Zou, Resveratrol Inhibits CD4+ T cell activation by enhancing the expression and activity of Sirt1, PloS one, vol.8, p.75139, 2013.

T. Akimova, Targeting sirtuin-1 alleviates experimental autoimmune colitis by induction of Foxp3+ T-regulatory cells, Mucosal immunology, vol.7, pp.1209-1220, 2014.

U. H. Beier, Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival, Molecular and cellular biology, vol.31, pp.1022-1029, 2011.

Y. Wang, Histone Deacetylase SIRT1 Negatively Regulates the Differentiation of Interleukin-9-Producing CD4(+) T Cells. Immunity, vol.44, pp.1337-1349, 2016.

E. J. Kim, J. H. Kho, M. R. Kang, and S. J. Um, Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity, Molecular cell, vol.28, pp.277-290, 2007.

C. W. Chen, DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia, Nature medicine, vol.21, pp.335-343, 2015.

J. Lu, SIRT1 counteracted the activation of STAT3 and NF-kappaB to repress the gastric cancer growth, International journal of clinical and experimental medicine, vol.7, pp.5050-5058, 2014.

R. Sestito, STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation, FASEB journal : official publication of the Federation of American Societies for Experimental Biology, vol.25, pp.916-927, 2011.

A. Bishayee, Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials, Cancer prevention research, vol.2, pp.409-418, 2009.

Y. M. Song, Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway, Autophagy, vol.11, pp.46-59, 2015.

Z. Gong, Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative, International journal of cancer. Journal international du cancer, vol.138, pp.1915-1927, 2016.

R. T. Chlebowski, Diabetes, metformin, and breast cancer in postmenopausal women, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.30, pp.2844-2852, 2012.

X. K. He, T. T. Su, J. M. Si, and L. M. Sun, Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis, Medicine, vol.95, p.2749, 2016.

M. Aldea, Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.35, pp.5101-5110, 2014.

I. Pernicova and M. Korbonits, Metformin--mode of action and clinical implications for diabetes and cancer, Nature reviews. Endocrinology, vol.10, pp.143-156, 2014.

M. Yin, J. Zhou, E. J. Gorak, and F. Quddus, Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis, The oncologist, vol.18, pp.1248-1255, 2013.

D. Zhao, Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma, International journal of cancer. Journal international du cancer, vol.136, pp.2556-2565, 2015.

Y. Sun, Metformin ameliorates the development of experimental autoimmune encephalomyelitis by regulating T helper 17 and regulatory T cells in mice, Journal of neuroimmunology, vol.292, pp.58-67, 2016.

, Liste des publications, pp.2013-2016

E. Limagne, M. Thibaudin, R. Euvrard, H. Berger, P. Chalons et al., En préparation Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX-bevacizumab drug treatment regimen, Sirtuin-1 (SIRT1) activation controls tumor growth by impeding Th17 differentiation via STAT3 deacetylation, 2016.

E. Limagne, A. Lançon, D. Delmas, M. Cherkaoui-malki, L. N. Nutrients-;-thibaudin et al., Human ectonucleotidase-expressing CD25 high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions, Resveratrol Interferes with IL1-?-Induced Pro-Inflammatory Paracrine Interaction between Primary Chondrocytes and Macrophages, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01438254

V. Derangère, J. D. Fumet, R. Boidot, L. Bengrine, E. Limagne et al., Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?, 2016.

M. Bruchard, C. Rebé, V. Derangère, D. Togbé, B. Ryffel et al., The receptor NLRP3 is a transcriptional regulator of TH2 differentiation, 2015.

E. Limagne, V. Cottet, A. K. Cotte, S. Hamza, P. Hillon et al., Potential role of oxidative DNA damage in the impact of PNPLA3 variant (rs 738409 C>G) in hepatocellular carcinoma risk, 2014.

D. J. Colin, E. Limagne, K. Ragot, G. Lizard, F. Ghiringhelli et al., The role of reactive oxygen species and subsequent DNA-damage response in the emergence of resistance towards resveratrol in colon cancer models, Cell Death Dis, 2014.

V. Derangère, A. Chevriaux, F. Courtaut, M. Bruchard, H. Berger et al., Liver X receptor ? activation induces pyroptosis of human and murine colon cancer cells, Cell Death Differ, 2014.

F. Mazué, D. Delmas, G. Murillo, D. Saleiro, E. Limagne et al., Differential protective effects of red wine polyphenol extracts (RWEs) on colon carcinogenesis, 2014.

V. Aires, B. Brassart, A. Carlier, A. Scagliarini, S. Mandard et al., A role for peroxisome proliferator-activated receptor gamma in resveratrol-induced colon cancer cell apoptosis, Mol Nutr Food Res, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-01016743

E. Limagne, V. Aires, A. K. Cotte, N. Latruffe, F. Ghiringhelli et al., Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death, Mol Nutr Food Res, 2013.

D. Delmas, V. Aires, D. J. Colin, E. Limagne, A. Scagliarini et al., Importance of lipid microdomains, rafts, in absorption, delivery, and biological effects of resveratrol, Ann N Y Acad Sci, vol.5, issue.11, pp.1121-1121, 2013.

G. I. Abelev, S. D. Perova, N. I. Khramkova, Z. A. Postnikova, and I. S. Irlin, Production of embryonal alpha-globulin by transplantable mouse hepatomas, Transplantation, vol.1, pp.174-80, 1963.

J. L. Adams, J. Smothers, R. Srinivasan, and A. Hoos, Big opportunities for small molecules in immuno-oncology, Nature reviews Drug discovery, vol.14, issue.9, pp.603-625, 2015.

V. Aires, E. Limagne, A. K. Cotte, N. Latruffe, F. Ghiringhelli et al., Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death, Molecular nutrition & food research, vol.57, issue.7, pp.1170-81, 2013.

L. B. Alexandrov, S. Nik-zainal, D. C. Wedge, S. A. Aparicio, S. Behjati et al., Signatures of mutational processes in human cancer, Consortium IBC, Consortium IM, vol.500, pp.415-436, 2013.

D. Alizadeh, M. Trad, N. T. Hanke, C. B. Larmonier, N. Janikashvili et al., Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer, Cancer research, vol.74, issue.1, pp.104-122, 2014.

J. M. Allan and L. B. Travis, Mechanisms of therapy-related carcinogenesis, Nature reviews Cancer, vol.5, issue.12, pp.943-55, 2005.

B. Almand, J. I. Clark, E. Nikitina, J. Van-beynen, N. R. English et al., Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer, Journal of immunology, vol.166, issue.1, pp.678-89, 2001.

F. Annunziato, L. Cosmi, F. Liotta, M. E. Romagnani, and S. , The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation, International immunology, vol.20, issue.11, pp.1361-1369, 2008.

L. Apetoh, F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz et al., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nature medicine, vol.13, issue.9, pp.1050-1059, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00316924

A. Aruga, E. Aruga, K. Tanigawa, D. K. Bishop, V. K. Sondak et al., Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role, Journal of immunology, vol.159, issue.2, pp.664-73, 1997.

C. Aspord, A. Pedroza-gonzalez, M. Gallegos, S. Tindle, E. C. Burton et al., Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development, The Journal of experimental medicine, vol.204, issue.5, pp.1037-1084, 2007.
DOI : 10.1084/jem.20061120
URL : http://europepmc.org/articles/pmc2118566?pdf=render

C. Badoual, S. Hans, J. Rodriguez, S. Peyrard, C. Klein et al., Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.12, issue.2, pp.465-72, 2006.

L. Baitsch, A. Legat, L. Barba, F. Marraco, S. A. Rivals et al., Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization, PloS one, vol.7, issue.2, p.30852, 2012.

A. Bamias, V. Koutsoukou, E. Terpos, M. L. Tsiatas, C. Liakos et al., Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy, Gynecologic oncology, vol.108, issue.2, pp.421-428, 2008.

J. Barbi, D. Pardoll, and F. Pan, Metabolic control of the Treg/Th17 axis, Immunological reviews, vol.252, issue.1, pp.52-77, 2013.

G. J. Bates, S. B. Fox, C. Han, R. D. Leek, J. F. Garcia et al., Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.24, issue.34, pp.5373-80, 2006.

L. Benevides, D. M. Da-fonseca, P. B. Donate, D. G. Tiezzi, D. Carvalho et al., IL17 Promotes Mammary Tumor Progression by Changing the Behavior of Tumor Cells and Eliciting Tumorigenic Neutrophils Recruitment, Cancer research, vol.75, issue.18, pp.3788-99, 2015.

J. A. Bennett, V. S. Rao, and M. S. Mitchell, Systemic bacillus Calmette-Guerin (BCG) activates natural suppressor cells, Proceedings of the National Academy of Sciences of the United States of America, vol.75, issue.10, pp.5142-5146, 1978.
DOI : 10.1073/pnas.75.10.5142
URL : http://www.pnas.org/content/75/10/5142.full.pdf

H. Berger, F. Vegran, M. Chikh, F. Gilardi, S. Ladoire et al., SOCS3 transactivation by PPARgamma prevents IL-17-driven cancer growth, Cancer research, vol.73, issue.12, pp.3578-90, 2013.
DOI : 10.1158/0008-5472.can-12-4018
URL : http://cancerres.aacrjournals.org/content/73/12/3578.full.pdf

G. Bindea, B. Mlecnik, M. Tosolini, A. Kirilovsky, M. Waldner et al., Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer, Immunity, vol.39, issue.4, pp.782-95, 2013.

L. Bingle, N. J. Brown, and C. E. Lewis, The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies, The Journal of pathology, vol.196, issue.3, pp.254-65, 2002.

S. D. Blackburn, H. Shin, W. N. Haining, T. Zou, C. J. Workman et al., Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection, Nature immunology, vol.10, issue.1, pp.29-37, 2009.

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus Docétaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, vol.373, pp.1627-1666, 2015.

J. Brahmer, K. L. Reckamp, P. Baas, L. Crino, W. E. Eberhardt et al., Nivolumab versus Docétaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, vol.373, pp.123-158, 2015.

J. R. Brahmer, S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, The New England journal of medicine, vol.366, issue.26, pp.2455-65, 2012.

H. Braumuller, T. Wieder, E. Brenner, S. Assmann, M. Hahn et al., T-helper-1-cell cytokines drive cancer into senescence, Nature, vol.494, issue.7437, pp.361-366, 2013.

D. Breitfeld, L. Ohl, E. Kremmer, J. Ellwart, F. Sallusto et al., Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production, The Journal of experimental medicine, vol.192, issue.11, pp.1545-52, 2000.

V. Bronte, E. Apolloni, A. Cabrelle, R. Ronca, P. Serafini et al., Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells, Blood, vol.96, issue.12, pp.3838-3884, 2000.

S. Broomfield, A. Currie, R. G. Van-der-most, M. Brown, I. Van-bruggen et al., Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy, Cancer research, vol.65, issue.17, pp.7580-7584, 2005.

M. Bruchard, G. Mignot, V. Derangere, F. Chalmin, A. Chevriaux et al., Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth, Nature medicine, vol.19, issue.1, pp.57-64, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00919371

J. F. Brunet, F. Denizot, M. F. Luciani, M. Roux-dosseto, M. Suzan et al., A new member of the immunoglobulin superfamily--CTLA-4, Nature, vol.328, issue.6127, pp.267-70, 1987.

R. J. Buckanovich, A. Facciabene, S. Kim, F. Benencia, D. Sasaroli et al., Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy, Nature medicine, vol.14, issue.1, pp.28-36, 2008.

A. Buckowitz, H. P. Knaebel, A. Benner, H. Blaker, J. Gebert et al., Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases, British journal of cancer, vol.92, issue.9, pp.1746-53, 2005.

A. Bugalho, C. Martins, Z. Silva, G. Nunes, A. S. Mendes et al., Immature myeloid cells and tolerogenic cytokine profile in lung adenocarcinoma metastatic lymph nodes assessed by endobronchial ultrasound, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.37, issue.1, pp.953-61, 2016.

S. K. Bunt, L. Yang, P. Sinha, V. K. Clements, J. Leips et al., Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression, Cancer research, vol.67, issue.20, pp.10019-10045, 2007.

M. Burnet, Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications, British medical journal, vol.1, issue.5023, pp.841-848, 1957.

M. Burnet, Cancer; a biological approach. I. The processes of control, British medical journal, vol.1, issue.5022, pp.779-86, 1957.

M. S. Caetano, H. Zhang, A. M. Cumpian, L. Gong, N. Unver et al., IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer, Cancer research, vol.76, issue.11, pp.3189-99, 2016.

G. Cai and G. J. Freeman, The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation, Immunological reviews, vol.229, issue.1, pp.244-58, 2009.

M. K. Callahan and J. D. Wolchok, At the bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy, Journal of leukocyte biology, vol.94, issue.1, pp.41-53, 2013.

M. Camus, M. Tosolini, B. Mlecnik, F. Pages, A. Kirilovsky et al., Coordination of intratumoral immune reaction and human colorectal cancer recurrence, Cancer research, vol.69, issue.6, pp.2685-93, 2009.

N. Casares, M. O. Pequignot, A. Tesniere, F. Ghiringhelli, S. Roux et al., Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death, The Journal of experimental medicine, vol.202, issue.12, pp.1691-701, 2005.

C. Cerboni, C. Fionda, A. Soriani, A. Zingoni, M. Doria et al., The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells, Frontiers in immunology, vol.4, p.508, 2014.
URL : https://hal.archives-ouvertes.fr/pasteur-01166963

E. Cha, M. Klinger, Y. Hou, C. Cummings, A. Ribas et al., Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients, Science translational medicine, vol.6, issue.238, pp.238-70, 2014.

F. Chalmin, S. Ladoire, G. Mignot, J. Vincent, M. Bruchard et al., Membraneassociated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells, The Journal of clinical investigation, vol.120, issue.2, pp.457-71, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00451697

F. Chalmin, G. Mignot, M. Bruchard, A. Chevriaux, F. Vegran et al., Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression, Immunity, vol.36, issue.3, pp.362-73, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00821485

C. C. Chang, G. Pirozzi, S. H. Wen, I. H. Chung, B. L. Chiu et al., Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy, The Journal of biological chemistry, vol.290, issue.44, pp.26562-75, 2015.

H. C. Chang, S. Sehra, R. Goswami, W. Yao, Q. Yu et al., The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation, Nature immunology, vol.11, issue.6, p.248, 2010.

M. P. Chao, S. Jaiswal, R. Weissman-tsukamoto, A. A. Alizadeh, A. J. Gentles et al., Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47, Science translational medicine, vol.2, issue.63, pp.63-94, 2010.
DOI : 10.1126/scitranslmed.3001375
URL : http://europepmc.org/articles/pmc4126904?pdf=render

G. Chen and L. A. Emens, Chemoimmunotherapy: reengineering tumor immunity, Cancer immunology, immunotherapy : CII, vol.62, issue.2, pp.203-219, 2013.
DOI : 10.1007/s00262-012-1388-0
URL : http://europepmc.org/articles/pmc3608094?pdf=render

L. Chen and D. B. Flies, Molecular mechanisms of T cell co-stimulation and co-inhibition, Nature reviews Immunology, vol.13, issue.4, pp.227-269, 2013.

W. C. Chen, Y. H. Lai, H. Y. Chen, H. R. Guo, I. J. Su et al., Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor, Histopathology, vol.63, issue.2, pp.225-258, 2013.

X. Chen, J. Wan, J. Liu, W. Xie, X. Diao et al., Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients, Lung cancer, vol.69, issue.3, pp.348-54, 2010.

Z. Chen and M. S. Freedman, CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis, Clinical immunology, vol.128, issue.2, pp.219-246, 2008.

P. Cheng, C. A. Corzo, N. Luetteke, B. Yu, S. Nagaraj et al., Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein, The Journal of experimental medicine, vol.205, issue.10, pp.2235-2284, 2008.

M. K. Choy and M. E. Phipps, MICA polymorphism: biology and importance in immunity and disease, Trends in molecular medicine, vol.16, issue.3, pp.97-106, 2010.
DOI : 10.1016/j.molmed.2010.01.002

S. Chugh, V. Anand, L. Swaroop, M. Sharma, A. Seth et al., Involvement of Th17 cells in patients of urothelial carcinoma of bladder, Human immunology, vol.74, issue.10, pp.1258-62, 2013.

M. Ciofani, A. Madar, C. Galan, M. Sellars, K. Mace et al., A validated regulatory network for Th17 cell specification, Cell, vol.151, issue.2, pp.289-303, 2012.
DOI : 10.1016/j.cell.2012.09.016
URL : https://doi.org/10.1016/j.cell.2012.09.016

W. B. Coley, The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893, Clinical orthopaedics and related research, issue.262, pp.3-11, 1991.

D. Colin, E. Limagne, S. Jeanningros, A. Jacquel, G. Lizard et al., Endocytosis of resveratrol via lipid rafts and activation of downstream signaling pathways in cancer cells, Cancer prevention research, vol.4, issue.7, pp.1095-106, 2011.

J. R. Conejo-garcia, F. Benencia, M. C. Courreges, E. Kang, M. -. Hadley et al., Tumorinfiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A, Nature medicine, vol.10, issue.9, pp.950-958, 2004.

C. A. Corzo, T. Condamine, L. Lu, M. J. Cotter, J. I. Youn et al., HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment, The Journal of experimental medicine, vol.207, issue.11, pp.2439-53, 2010.

L. Cottone, A. Capobianco, C. Gualteroni, C. Perrotta, M. E. Bianchi et al., 5-Fluorouracil causes leukocytes attraction in the peritoneal cavity by activating 249 autophagy and HMGB1 release in colon carcinoma cells, International journal of cancer Journal international du cancer, vol.136, issue.6, pp.1381-1390, 2015.

C. A. Crane, A. Panner, J. C. Murray, S. P. Wilson, H. Xu et al., PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer, Oncogene, vol.28, issue.2, pp.306-318, 2009.

M. Croft, L. Carter, S. L. Swain, and R. W. Dutton, Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles, The Journal of experimental medicine, vol.180, issue.5, pp.1715-1743, 1994.

N. Y. Crowe, J. M. Coquet, S. P. Berzins, K. Kyparissoudis, R. Keating et al., Differential antitumor immunity mediated by NKT cell subsets in vivo, The Journal of experimental medicine, vol.202, issue.9, pp.1279-88, 2005.

N. Y. Crowe, M. J. Smyth, and D. I. Godfrey, A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas, The Journal of experimental medicine, vol.196, issue.1, pp.119-146, 2002.

M. Crowther, N. J. Brown, E. T. Bishop, and C. E. Lewis, Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors, Journal of leukocyte biology, vol.70, issue.4, pp.478-90, 2001.

D. J. Cua, J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce et al., Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain, Nature, vol.421, issue.6924, pp.744-752, 2003.

J. F. Curtin, N. Liu, M. Candolfi, W. Xiong, H. Assi et al., HMGB1 mediates endogenous TLR2 activation and brain tumor regression, PLoS medicine, vol.6, issue.1, p.10, 2009.
DOI : 10.1371/journal.pmed.1000010
URL : https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1000010&type=printable

M. D'asaro, L. Mendola, C. , D. Liberto, D. Orlando et al., V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronatesensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells, Journal of immunology, vol.184, issue.6, pp.3260-3268, 2010.

E. V. Dang, J. Barbi, H. Y. Yang, D. Jinasena, H. Yu et al., Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1, vol.146, pp.772-84, 2011.

V. Dardalhon, A. Awasthi, H. Kwon, G. Galileos, W. Gao et al., , 2008.

, Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells, Nature immunology, vol.9, issue.12, pp.1347-55

S. Deaglio, K. M. Dwyer, W. Gao, D. Friedman, A. Usheva et al., Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression, The Journal of experimental medicine, vol.204, issue.6, pp.1257-65, 2007.
DOI : 10.1084/jem.20062512
URL : http://jem.rupress.org/content/204/6/1257.full.pdf

C. Denkert, S. Loibl, A. Noske, M. Roller, B. M. Muller et al., Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.28, issue.1, pp.105-118, 2010.

D. Biase, S. Lee, C. Brandhorst, S. Manes, B. Buono et al., Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity, Cancer cell, vol.30, issue.1, pp.136-182, 2016.

D. Carlo, E. Bocca, P. Emionite, L. Cilli, M. Cipollone et al., Mechanisms of the antitumor activity of human Vgamma9Vdelta2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma, Molecular therapy : the journal of the American Society of Gene Therapy, vol.21, issue.5, pp.1034-1077, 2013.

F. Dieli, D. Vermijlen, F. Fulfaro, N. Caccamo, S. Meraviglia et al., Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer, Cancer research, vol.67, issue.15, pp.7450-7457, 2007.

M. C. Dieu-nosjean, A. M. Danel, C. Heudes, D. Wislez, M. Poulot et al., Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.26, issue.27, pp.4410-4417, 2008.
DOI : 10.1200/jco.2007.15.0284

A. L. Doedens, C. Stockmann, M. P. Rubinstein, D. Liao, N. Zhang et al., Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression, Cancer research, vol.70, pp.7465-75, 2010.

R. Dolcetti, A. Viel, C. Doglioni, A. Russo, M. Guidoboni et al., High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability, The American journal of pathology, vol.154, issue.6, pp.1805-1818, 1999.

T. Domoszlai, A. Martincuks, D. Fahrenkamp, H. Schmitz-van-de-leur, A. Kuster et al., Consequences of the disease-related L78R mutation for dimerization and activity of STAT3, Journal of cell science, vol.127, pp.1899-910, 2014.

R. T. Dorsam and J. S. Gutkind, G-protein-coupled receptors and cancer, Nature reviews Cancer, vol.7, issue.2, pp.79-94, 2007.

R. Du, H. Zhao, F. Yan, and H. Li, IL-17+Foxp3+ T cells: an intermediate differentiation stage between Th17 cells and regulatory T cells, Journal of leukocyte biology, vol.96, issue.1, pp.39-48, 2014.

T. J. Duncan, P. Rolland, S. Deen, I. V. Scott, D. T. Liu et al., Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.13, issue.14, pp.4139-4184, 2007.

G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, Cancer immunoediting: from immunosurveillance to tumor escape, Nature immunology, vol.3, issue.11, pp.991-999, 2002.

G. P. Dunn, L. J. Old, and R. D. Schreiber, The immunobiology of cancer immunosurveillance and immunoediting, Immunity, vol.21, issue.2, pp.137-185, 2004.

G. P. Dunn, K. C. Sheehan, L. J. Old, and R. D. Schreiber, IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression, Cancer research, vol.65, issue.8, pp.3447-53, 2005.

N. M. Durham, C. J. Nirschl, C. M. Jackson, J. Elias, C. M. Kochel et al., , 2014.

, LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo, Lymphocyte Activation Gene, vol.3, issue.11, p.109080

Z. Faghih, S. Rezaeifard, A. Safaei, A. Ghaderi, and N. Erfani, IL-17 and IL-4 producing CD8+ T cells in tumor draining lymph nodes of breast cancer patients: positive association with tumor progression, Iranian journal of immunology : IJI, vol.10, issue.4, pp.193-204, 2013.

L. Fehrenbacher, A. Spira, M. Ballinger, M. Kowanetz, J. Vansteenkiste et al., Atezolizumab versus docétaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet, vol.387, pp.1837-1883, 2016.

I. J. Fidler, Tumor heterogeneity and the biology of cancer invasion and metastasis, Cancer research, vol.38, issue.9, pp.2651-60, 1978.

P. Filipazzi, R. Valenti, V. Huber, L. Pilla, P. Canese et al., Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colonystimulation factor-based antitumor vaccine, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.25, issue.18, pp.2546-53, 2007.

K. Fischer, P. Hoffmann, S. Voelkl, N. Meidenbauer, J. Ammer et al., Inhibitory effect of tumor cell-derived lactic acid on human T cells, Blood, vol.109, issue.9, pp.3812-3821, 2007.

E. J. Foley, Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin, Cancer research, vol.13, issue.12, pp.835-842, 1953.

J. H. Fraser, M. Rincon, K. D. Mccoy, L. Gros, and G. , CTLA4 ligation attenuates AP-1, NFAT and NF-kappaB activity in activated T cells, European journal of immunology, vol.29, issue.3, pp.838-882, 1999.

D. T. Frederick, A. Piris, A. P. Cogdill, Z. A. Cooper, C. Lezcano et al., BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.19, issue.5, pp.1225-1256, 2013.

G. J. Freeman, A. J. Long, Y. Iwai, K. Bourque, T. Chernova et al., Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, The Journal of experimental medicine, vol.192, issue.7, pp.1027-1061, 2000.

D. M. Frey, R. A. Droeser, C. T. Viehl, I. Zlobec, A. Lugli et al., High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients, International journal of cancer Journal international du cancer, vol.126, issue.11, pp.2635-2678, 2010.

W. H. Fridman, F. Pages, C. Sautes-fridman, and J. Galon, The immune contexture in human tumours: impact on clinical outcome, Nature reviews Cancer, vol.12, issue.4, pp.298-306, 2012.

M. Fujita, G. Kohanbash, W. Fellows-mayle, R. L. Hamilton, Y. Komohara et al., COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells, Cancer research, vol.71, issue.7, pp.2664-74, 2011.

D. Gabrilovich, T. Ishida, T. Oyama, S. Ran, V. Kravtsov et al., Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo, Blood, vol.92, issue.11, pp.4150-66, 1998.

D. I. Gabrilovich, T. Ishida, S. Nadaf, J. E. Ohm, and D. P. Carbone, Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.5, issue.10, pp.2963-70, 1999.

S. L. Gaffen, R. Jain, A. V. Garg, and D. J. Cua, The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing, Nature reviews Immunology, vol.14, issue.9, pp.585-600, 2014.

G. Gallina, L. Dolcetti, P. Serafini, D. Santo, C. Marigo et al., Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells, The Journal of clinical investigation, vol.116, issue.10, pp.2777-90, 2006.

S. Gallucci, M. Lolkema, and P. Matzinger, Natural adjuvants: endogenous activators of dendritic cells, Nature medicine, vol.5, issue.11, pp.1249-55, 1999.

L. Galluzzi, O. Kepp, and G. Kroemer, Mitochondria: master regulators of danger signalling, Nature reviews Molecular cell biology, vol.13, issue.12, pp.780-788, 2012.

J. Galon, A. Costes, F. Sanchez-cabo, A. Kirilovsky, B. Mlecnik et al., Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, vol.313, issue.5795, pp.1960-1964

Q. Gao, X. Y. Wang, S. J. Qiu, J. Zhou, Y. H. Shi et al., Tumor stroma reactionrelated gene signature predicts clinical outcome in human hepatocellular carcinoma, Cancer science, vol.102, issue.8, pp.1522-1553, 2011.

A. D. Garg, D. V. Krysko, P. Vandenabeele, and P. Agostinis, Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin, Cancer immunology, immunotherapy : CII, vol.61, issue.2, pp.215-236, 2012.

A. D. Garg, D. V. Krysko, T. Verfaillie, A. Kaczmarek, G. B. Ferreira et al., A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death, The EMBO journal, vol.31, issue.5, pp.1062-79, 2012.

L. Gattinoni, E. Lugli, Y. Ji, Z. Pos, C. M. Paulos et al., A human memory T cell subset with stem cell-like properties, Nature medicine, vol.17, issue.10, pp.1290-1297, 2011.

A. C. Gavino, K. Nahmod, U. Bharadwaj, G. Makedonas, D. J. Tweardy et al., STAT3 inhibition prevents lung inflammation, remodeling, and accumulation of Th2 and Th17 cells in a murine asthma model, Allergy Gertner, vol.113, pp.4875-84, 1920.

H. Ghebeh, S. Mohammed, A. Al-omair, A. Qattan, C. Lehe et al., The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors, Neoplasia, vol.8, issue.3, pp.190-198, 2006.

C. Ghirelli, F. Reyal, M. Jeanmougin, R. Zollinger, P. Sirven et al., Breast Cancer Cell-Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes, vol.75, pp.2775-87, 2015.

F. Ghiringhelli, L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma et al., Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors, Nature medicine, vol.15, issue.10, pp.1170-1178, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00419823

F. Ghiringhelli, N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin et al., CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative, European journal of immunology, vol.34, issue.2, pp.336-380, 2004.

M. Gobert, I. Treilleux, N. Bendriss-vermare, T. Bachelot, S. Goddard-leon et al., Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome, Cancer research, vol.69, issue.5, pp.2000-2009, 2009.

S. Gonzalez, A. Lopez-soto, B. Suarez-alvarez, A. Lopez-vazquez, and C. Lopez-larrea, NKG2D ligands: key targets of the immune response, Trends in immunology, vol.29, issue.8, pp.397-403, 2008.

L. Gorelik and R. A. Flavell, Transforming growth factor-beta in T-cell biology, Nature reviews Immunology, vol.2, issue.1, pp.46-53, 2002.

V. G. Gorgoulis, P. Zacharatos, A. Kotsinas, D. Kletsas, G. Mariatos et al., (CD54) expression in an NF-kappaBindependent manner, The EMBO journal, vol.22, issue.7, pp.1567-78, 2003.

A. B. Gottlieb, R. T. Matheson, A. Menter, C. L. Leonardi, R. M. Day et al., Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study, Journal of drugs in dermatology : JDD, vol.12, issue.8, pp.888-97, 2013.

B. Gran, G. X. Zhang, S. Yu, J. Li, X. H. Chen et al., IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination, Journal of immunology, vol.169, issue.12, pp.7104-7114, 2002.

G. A. Grant and J. F. Miller, Effect of neonatal thymectomy on the induction of sarcomata in C57 BL mice, Nature, vol.205, issue.976, pp.1124-1129, 1965.

J. F. Grosso, C. C. Kelleher, T. J. Harris, C. H. Maris, E. L. Hipkiss et al., LAG-3 regulates CD8+ T cell accumulation and effector function in murine self-and tumor-tolerance systems, The Journal of clinical investigation, vol.117, issue.11, pp.3383-92, 2007.
DOI : 10.1172/jci31184
URL : http://www.jci.org/articles/view/31184/files/pdf

C. Gu-trantien, S. Loi, S. Garaud, C. Equeter, M. Libin et al., CD4(+) follicular helper T cell infiltration predicts breast cancer survival, The Journal of clinical investigation, vol.123, issue.7, pp.2873-92, 2013.
DOI : 10.1172/jci67428
URL : http://www.jci.org/articles/view/67428/files/pdf

N. Halama, S. Michel, M. Kloor, I. Zoernig, A. Benner et al., Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy, Cancer research, vol.71, issue.17, pp.5670-5677, 2011.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, issue.5, p.254, 2011.

E. M. Hanson, V. K. Clements, P. Sinha, D. Ilkovitch, and S. Ostrand-rosenberg, Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells, Journal of immunology, vol.183, issue.2, pp.937-981, 2009.
DOI : 10.4049/jimmunol.0804253
URL : http://www.jimmunol.org/content/183/2/937.full.pdf

L. E. Harrington, R. D. Hatton, P. R. Mangan, H. Turner, T. L. Murphy et al., , 2005.

W. D. Hastings, D. E. Anderson, N. Kassam, K. Koguchi, E. A. Greenfield et al., TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines, European journal of immunology, vol.39, issue.9, pp.2492-501, 2009.
DOI : 10.1002/eji.200939274
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1002/eji.200939274

Y. Hayakawa, K. Takeda, H. Yagita, L. Van-kaer, I. Saiki et al., Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways, Journal of immunology, vol.166, issue.10, pp.6012-6020, 2001.

D. He, H. Li, N. Yusuf, C. A. Elmets, J. Li et al., IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells, Journal of immunology, vol.184, issue.5, pp.2281-2289, 2010.

D. L. Herber, W. Cao, Y. Nefedova, S. V. Novitskiy, S. Nagaraj et al., Lipid accumulation and dendritic cell dysfunction in cancer, Nature medicine, vol.16, issue.8, pp.880-886, 2010.

R. S. Herbst, J. C. Soria, M. Kowanetz, G. D. Fine, O. Hamid et al., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, vol.515, issue.7528, pp.563-570, 2014.

A. Hervieu, C. Rebe, F. Vegran, F. Chalmin, M. Bruchard et al., Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth, The Journal of investigative dermatology, vol.133, issue.2, pp.499-508, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00857892

S. Hinz, A. Trauzold, L. Boenicke, C. Sandberg, S. Beckmann et al., Bcl-XL protects pancreatic adenocarcinoma cells against CD95-and TRAIL-receptor-mediated apoptosis, Oncogene, vol.19, issue.48, pp.5477-86, 2000.

K. Hiraoka, M. Miyamoto, Y. Cho, M. Suzuoki, T. Oshikiri et al., Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma, British journal of cancer, vol.94, issue.2, pp.275-80, 2006.

M. Hobart, V. Ramassar, N. Goes, J. Urmson, and P. F. Halloran, The induction of class I and II major histocompatibility complex by allogeneic stimulation is dependent on the transcription factor interferon regulatory factor 1 (IRF-1): observations in IRF-1 knockout mice, Transplantation, vol.62, issue.12, pp.1895-901, 1996.

B. Hoechst, J. Gamrekelashvili, M. P. Manns, T. F. Greten, and F. Korangy, Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells, Blood, vol.117, issue.24, pp.6532-6573, 2011.

W. Holtmeier and D. Kabelitz, ) gammadelta T cells link innate and adaptive immune responses, Chemical immunology and allergy, vol.86, pp.151-83, 2005.
DOI : 10.1159/000086659

N. Horikawa, K. Abiko, N. Matsumura, J. Hamanishi, T. Baba et al., Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells, TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients, vol.21, pp.3771-82, 2015.

C. E. Hu, J. Gan, R. D. Zhang, Y. R. Cheng, and G. J. Huang, Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function, Scandinavian journal of gastroenterology, vol.46, issue.2, pp.156-64, 2011.

A. Huang, B. Zhang, B. Wang, F. Zhang, K. X. Fan et al., Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients, Cancer immunology, immunotherapy : CII, vol.62, issue.9, pp.1439-51, 2013.

B. Huang, P. Y. Pan, Q. Li, A. I. Sato, D. E. Levy et al., Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host, Cancer research, vol.66, issue.2, pp.1123-1154, 2006.

B. Huard, M. Tournier, T. Hercend, F. Triebel, and F. Faure, Lymphocyte-activation gene, 1994.

, /major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes, European journal of immunology, vol.24, issue.12, pp.3216-3237

M. Huber, S. Heink, H. Grothe, A. Guralnik, K. Reinhard et al., A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity, European journal of immunology, vol.39, issue.7, pp.1716-1741, 2009.

Z. Husain, Y. Huang, P. Seth, and V. P. Sukhatme, Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells, Journal of immunology, vol.191, issue.3, pp.1486-95, 2013.

M. Ilie, E. Long-mira, C. Bence, C. Butori, S. Lassalle et al., Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies, Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, vol.27, issue.1, pp.147-53, 2016.

T. Inozume, K. Hanada, Q. J. Wang, and J. C. Yang, IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells, Journal of immunotherapy, vol.32, issue.2, pp.109-126, 2009.

Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo, Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death, The EMBO journal, vol.11, issue.11, pp.3887-95, 1992.

I. I. Ivanov, B. S. Mckenzie, L. Zhou, C. E. Tadokoro, A. Lepelley et al., The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells, Cell, vol.126, issue.6, pp.1121-1154, 2006.

Y. Iwakura and H. Ishigame, The IL-23/IL-17 axis in inflammation, The Journal of clinical investigation, vol.116, issue.5, pp.1218-1240, 2006.

C. Jackaman, D. Majewski, S. A. Fox, A. K. Nowak, and D. J. Nelson, Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo, Cancer immunology, immunotherapy : CII, vol.61, issue.12, pp.2343-56, 2012.

E. Jager, M. Ringhoffer, J. Karbach, M. Arand, F. Oesch et al., Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo, International journal of cancer Journal international du cancer, vol.66, issue.4, pp.470-476, 1996.

D. B. Johnson, C. Peng, and J. A. Sosman, Nivolumab in melanoma: latest evidence and clinical potential, Therapeutic advances in medical oncology, vol.7, pp.97-106, 2015.

D. H. Kaplan, V. Shankaran, A. S. Dighe, E. Stockert, M. Aguet et al., Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice, Proceedings of the National Academy of Sciences of the United States of America, vol.95, issue.13, pp.7556-61, 1998.

S. Karakhanova, E. Ryschich, B. Mosl, S. Harig, D. Jager et al., Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma, British journal of cancer, vol.112, issue.6, pp.1027-1063, 2015.

T. Kataoka, M. Schroter, M. Hahne, P. Schneider, M. Irmler et al., FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation, Journal of immunology, vol.161, issue.8, pp.3936-3978, 1998.

J. R. Kim, Y. J. Moon, K. S. Kwon, J. S. Bae, S. Wagle et al., Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas, PloS one, vol.8, issue.12, p.82870, 2013.

J. S. Kim, T. Sklarz, L. B. Banks, M. Gohil, A. T. Waickman et al., Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways, Nature immunology, vol.14, issue.6, pp.611-619, 2013.

M. Y. Kim, J. Koh, S. Kim, H. Go, Y. K. Jeon et al., Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumorinfiltrating T cells and the status of oncogenic drivers, Lung cancer, vol.88, issue.1, pp.24-33, 2015.

S. Kim, M. Y. Kim, J. Koh, H. Go, D. S. Lee et al., Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas, European journal of cancer, vol.51, issue.17, pp.2698-707, 2015.

H. Kimura, K. Sakai, T. Arao, T. Shimoyama, T. Tamura et al., Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor, Cancer science, vol.98, issue.8, pp.1275-80, 2007.

J. M. Kirkwood, M. S. Ernstoff, C. A. Davis, M. Reiss, R. Ferraresi et al., Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers, Annals of internal medicine, vol.103, issue.1, pp.32-38, 1985.

H. Kitamura, K. Iwakabe, T. Yahata, S. Nishimura, A. Ohta et al., The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells, The Journal of experimental medicine, vol.189, issue.7, pp.1121-1129, 1999.

M. Kleinewietfeld, A. Manzel, J. Titze, H. Kvakan, N. Yosef et al., Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells, Nature, vol.496, issue.7446, pp.518-540, 2013.

H. Kobayashi, Y. Tanaka, H. Shimmura, N. Minato, and K. Tanabe, Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta Tcells in a patient with renal cell carcinoma, Anticancer research, vol.30, issue.2, pp.575-584, 2010.

K. N. Kodumudi, K. Woan, D. L. Gilvary, E. Sahakian, S. Wei et al., A novel chemoimmunomodulating property of docétaxel: suppression of myeloid-derived suppressor cells in tumor bearers, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.16, issue.18, pp.4583-94, 2010.

C. M. Koebel, W. Vermi, J. B. Swann, N. Zerafa, S. J. Rodig et al., , 2007.

, Adaptive immunity maintains occult cancer in an equilibrium state, Nature, vol.450, issue.7171, pp.903-910

F. Koinis, E. K. Vetsika, D. Aggouraki, E. Skalidaki, A. Koutoulaki et al., Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells' Subpopulations in the Peripheral Blood of Patients with Non-Small Cell Lung Cancer, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol.11, issue.8, pp.1263-72, 2016.

R. Kokkola, A. Andersson, G. Mullins, T. Ostberg, C. J. Treutiger et al., RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages, Scandinavian journal of immunology, vol.61, issue.1, pp.1-9, 2005.

M. Korbelik, J. Banath, J. Sun, D. Canals, Y. A. Hannun et al., Ceramide and sphingosine-1-phosphate act as photodynamic therapy-elicited damage-associated molecular patterns: cell surface exposure, International immunopharmacology, vol.20, issue.2, pp.359-65, 2014.

T. Korn, E. Bettelli, W. Gao, A. Awasthi, A. Jager et al., IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells, Nature, vol.448, issue.7152, pp.484-491, 2007.

T. Korn, E. Bettelli, M. Oukka, and V. K. Kuchroo, IL-17 and Th17 Cells, Annual review of immunology, vol.27, pp.485-517, 2009.

M. Kortylewski, M. Kujawski, T. Wang, S. Wei, S. Zhang et al., Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity, Nature medicine, vol.11, issue.12, pp.1314-1335, 2005.

G. Kroemer, L. Senovilla, L. Galluzzi, F. Andre, and L. Zitvogel, Natural and therapy-induced immunosurveillance in breast cancer, Nature medicine, vol.21, issue.10, pp.1128-1166, 2015.

J. Krueger, J. D. Clark, M. Suarez-farinas, J. Fuentes-duculan, I. Cueto et al., Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study, The Journal of allergy and clinical immunology, vol.137, issue.4, pp.1079-90, 2016.

I. Kryczek, M. Banerjee, P. Cheng, L. Vatan, W. Szeliga et al., Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments, Blood, vol.114, issue.6, pp.1141-1150, 2009.

D. V. Krysko, A. D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis et al., Immunogenic cell death and DAMPs in cancer therapy, Nature reviews Cancer, vol.12, issue.12, pp.860-75, 2012.

G. Y. Ku, J. Yuan, D. B. Page, S. E. Schroeder, K. S. Panageas et al., Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival, Cancer, vol.116, issue.7, pp.1767-75, 2010.

S. Ladoire, L. Arnould, L. Apetoh, B. Coudert, F. Martin et al., Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.14, issue.8, pp.2413-2433, 2008.

S. Ladoire, D. Enot, F. Andre, L. Zitvogel, and G. Kroemer, Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy, Oncoimmunology, vol.5, issue.2, p.1082706, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01448304

S. Ladoire, G. Mignot, S. Dabakuyo, L. Arnould, L. Apetoh et al., situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival, vol.224, pp.389-400, 2011.

J. Larkin, V. Chiarion-sileni, R. Gonzalez, J. J. Grob, C. L. Cowey et al., Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, The New England journal of medicine, vol.373, issue.1, pp.23-34, 2015.

Y. Latchman, C. R. Wood, T. Chernova, D. Chaudhary, M. Borde et al., PD-L2 is a second ligand for PD-1 and inhibits T cell activation, Nature immunology, vol.2, issue.3, pp.261-269, 2001.

D. T. Le, J. N. Uram, H. Wang, B. R. Bartlett, H. Kemberling et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, vol.372, pp.2509-2529, 2015.

H. K. Le, L. Graham, E. Cha, J. K. Morales, M. H. Manjili et al., Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice, International immunopharmacology, vol.9, issue.7-8, pp.900-909, 2009.

D. R. Leach, M. F. Krummel, and J. P. Allison, Enhancement of antitumor immunity by CTLA-4 blockade, Science, vol.271, issue.5256, pp.1734-1740, 1996.

J. Lecouter, C. Zlot, M. Tejada, F. Peale, and N. Ferrara, Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization, Proceedings of the National Academy of Sciences of the United States of America, vol.101, issue.48, pp.16813-16821, 2004.

A. Legat, D. E. Speiser, H. Pircher, D. Zehn, F. Marraco et al., Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8 T Cells, Frontiers in immunology, vol.4, p.455, 2013.

W. J. Leonard and R. Spolski, Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation, Nature reviews Immunology, vol.5, issue.9, pp.688-98, 2005.

M. Lepore, C. De-lalla, S. R. Gundimeda, H. Gsellinger, M. Consonni et al., A novel selflipid antigen targets human T cells against CD1c(+) leukemias, The Journal of experimental medicine, vol.211, issue.7, pp.1363-77, 2014.

C. Leporini, M. Ammendola, I. Marech, G. Sammarco, R. Sacco et al., Targeting mast cells in gastric cancer with special reference to bone metastases, World journal of gastroenterology, vol.21, issue.37, pp.10493-501, 2015.

W. J. Lesterhuis, J. Salmons, A. K. Nowak, E. N. Rozali, A. Khong et al., Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity, PloS one, vol.8, issue.4, p.61895, 2013.

H. Li, B. Ciric, J. Yang, H. Xu, D. C. Fitzgerald et al., Intravenous tolerance modulates macrophage classical activation and antigen presentation in experimental autoimmune encephalomyelitis, Journal of neuroimmunology, vol.208, issue.1-2, pp.54-60, 2009.

J. Y. Li, X. F. Duan, L. P. Wang, Y. J. Xu, L. Huang et al., Selective depletion of regulatory T cell subsets by docétaxel treatment in patients with nonsmall cell lung cancer, Journal of immunology research, vol.2014, p.286170, 2014.

L. Li, C. Yang, Z. Zhao, B. Xu, M. Zheng et al., , 2015.

, /2-and Th17/T regulatorycell balances in patients with renal cell carcinoma, Molecular medicine reports, vol.11, issue.2, pp.947-53

N. Li, Y. Wang, K. Forbes, K. M. Vignali, B. S. Heale et al., Metalloproteases regulate T-cell proliferation and effector function via LAG-3, The EMBO journal, vol.26, issue.2, pp.494-504, 2007.

Z. Li, J. Jiang, Z. Wang, J. Zhang, M. Xiao et al., Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis, Cancer research, vol.68, issue.21, pp.8687-94, 2008.

C. I. Liakou, A. Kamat, D. N. Tang, H. Chen, J. Sun et al., CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients, Proceedings of the National Academy of Sciences of the United States of America, vol.105, issue.39, pp.14987-92, 2008.

E. Limagne, R. Euvrard, M. Thibaudin, C. Rebe, V. Derangere et al., Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen, Cancer research, vol.76, issue.18, pp.5241-52, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01413261

E. Limagne, A. Lancon, D. Delmas, M. Cherkaoui-malki, and N. Latruffe, Resveratrol Interferes with IL1-beta-Induced Pro-Inflammatory Paracrine Interaction between Primary Chondrocytes and Macrophages, Nutrients, vol.8, issue.5, 2016.

D. C. Lin, C. M. Bullock, F. J. Ehlert, J. L. Chen, H. Tian et al., Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor, The Journal of biological chemistry, vol.277, issue.22, pp.19276-80, 2002.

P. S. Linsley, J. L. Greene, W. Brady, J. Bajorath, J. A. Ledbetter et al., Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors, Immunity, vol.1, issue.9, pp.793-801, 1994.

F. T. Liu and G. A. Rabinovich, Galectins as modulators of tumour progression, Nature reviews Cancer, vol.5, issue.1, pp.29-41, 2005.

J. Liu, Y. Duan, X. Cheng, X. Chen, W. Xie et al., IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma, Biochemical and biophysical research communications, vol.407, issue.2, pp.348-54, 2011.

W. M. Liu, D. W. Fowler, P. Smith, and A. G. Dalgleish, Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses, British journal of cancer, vol.102, issue.1, pp.115-138, 2010.

S. Lob, A. Konigsrainer, H. G. Rammensee, G. Opelz, and P. Terness, Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?, Nature reviews Cancer, vol.9, issue.6, pp.445-52, 2009.

M. T. Lotze, A. E. Chang, C. A. Seipp, C. Simpson, J. T. Vetto et al., High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings, Jama, vol.256, issue.22, pp.3117-3141, 1986.

E. Lozano, M. Dominguez-villar, V. Kuchroo, and D. A. Hafler, The TIGIT/CD226 axis regulates human T cell function, Journal of immunology, vol.188, issue.8, pp.3869-75, 2012.

Y. Lu, S. Hong, H. Li, J. Park, B. Hong et al., Th9 cells promote antitumor immune responses in vivo, The Journal of clinical investigation, vol.122, issue.11, pp.4160-71, 2012.

L. Lv, K. Pan, X. D. Li, K. L. She, J. J. Zhao et al., The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma, PloS one, vol.6, issue.3, p.18219, 2011.

Y. Ma, S. Adjemian, H. Yang, J. P. Catani, D. Hannani et al., ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy, Oncoimmunology, vol.2, issue.6, p.24568, 2013.
URL : https://hal.archives-ouvertes.fr/hal-02047415

Y. D. Mahnke, T. M. Brodie, F. Sallusto, M. Roederer, and E. Lugli, The who's who of T-cell differentiation: human memory T-cell subsets, European journal of immunology, vol.43, issue.11, pp.2797-809, 2013.

J. R. Maleckar and L. A. Sherman, The composition of the T cell receptor repertoire in nude mice, Journal of immunology, vol.138, issue.11, pp.3873-3879, 1987.

E. Maniati and T. Hagemann, IL-17 mediates resistance to anti-VEGF therapy, Nature medicine, vol.19, issue.9, pp.1092-1096, 2013.

M. M. Markiewski, R. A. Deangelis, F. Benencia, S. K. Ricklin-lichtsteiner, A. Koutoulaki et al., Modulation of the antitumor immune response by complement, Nature immunology, vol.9, issue.11, pp.1225-1260, 2008.

F. Martin, L. Apetoh, and F. Ghiringhelli, Controversies on the role of Th17 in cancer: a TGFbeta-dependent immunosuppressive activity? Trends in molecular medicine, vol.18, pp.742-751, 2012.

I. Martins, Y. Wang, M. Michaud, Y. Ma, A. Q. Sukkurwala et al., Molecular mechanisms of ATP secretion during immunogenic cell death, Cell death and differentiation, vol.21, issue.1, pp.79-91, 2014.

J. Matsuzaki, S. Gnjatic, P. Mhawech-fauceglia, A. Beck, A. Miller et al., Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer, Proceedings of the National Academy of Sciences of the United States of America, vol.107, issue.17, pp.7875-80, 2010.

P. Matzinger, Tolerance, danger, and the extended family, Annual review of immunology, vol.12, pp.991-1045, 1994.

C. Medrek, F. Ponten, K. Jirstrom, and K. Leandersson, The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients, BMC cancer, vol.12, p.306, 2012.

M. Mesquida, A. Leszczynska, V. Llorenc, and A. A. , Interleukin-6 blockade in ocular inflammatory diseases, Clinical and experimental immunology, vol.176, issue.3, pp.301-310, 2014.

C. Meyer, L. Cagnon, C. M. Costa-nunes, P. Baumgaertner, N. Montandon et al., Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab, Cancer immunology, immunotherapy : CII, vol.63, issue.3, pp.247-57, 2014.

M. Michaud, A. Q. Sukkurwala, I. Martins, S. Shen, L. Zitvogel et al., Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39, Oncoimmunology, vol.1, issue.3, pp.393-395, 2012.

B. Mlecnik, M. Tosolini, P. Charoentong, A. Kirilovsky, G. Bindea et al., Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer, Gastroenterology, vol.138, issue.4, pp.1429-1469, 2010.

B. Molon, S. Ugel, D. Pozzo, F. Soldani, C. Zilio et al., Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells, The Journal of experimental medicine, vol.208, issue.10, pp.1949-62, 2011.

L. Monney, C. A. Sabatos, J. L. Gaglia, A. Ryu, H. Waldner et al., Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease, Nature, vol.415, issue.6871, pp.536-577, 2002.

I. Monteleone, A. Rizzo, M. Sarra, G. Sica, P. Sileri et al., Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract, Gastroenterology, vol.141, issue.1, p.1, 2011.

A. Moretta, Natural killer cells and dendritic cells: rendezvous in abused tissues, Nature reviews Immunology, vol.2, issue.12, pp.957-64, 2002.

T. R. Mosmann, H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman, Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins, Journal of immunology, vol.136, issue.7, pp.2348-57, 1986.

G. T. Motz and G. Coukos, The parallel lives of angiogenesis and immunosuppression: cancer and other tales, Nature reviews Immunology, vol.11, issue.10, pp.702-713, 2011.

G. T. Motz, S. P. Santoro, L. P. Wang, T. Garrabrant, R. R. Lastra et al., Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors, Nature medicine, vol.20, issue.6, pp.607-622, 2014.

R. Mukasa, A. Balasubramani, Y. K. Lee, S. K. Whitley, B. T. Weaver et al., Epigenetic instability of cytokine and transcription factor gene loci underlies plasticity of the T helper 17 cell lineage, Immunity, vol.32, issue.5, pp.616-643, 2010.

N. Muller-hermelink, H. Braumuller, B. Pichler, T. Wieder, R. Mailhammer et al., TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis, Cancer cell, vol.13, issue.6, pp.507-525, 2008.

P. Muranski and N. P. Restifo, Essentials of Th17 cell commitment and plasticity, Blood, vol.121, issue.13, pp.2402-2416, 2013.

S. Nagaraj, J. I. Youn, and D. I. Gabrilovich, Reciprocal relationship between myeloid-derived suppressor cells and T cells, Journal of immunology, vol.191, issue.1, pp.17-23, 2013.

B. Nakata, Y. Q. Wang, M. Yashiro, N. Nishioka, H. Tanaka et al., Prognostic value of microsatellite instability in resectable pancreatic cancer, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.8, issue.8, pp.2536-2576, 2002.

Y. Narita, D. Wakita, T. Ohkur, K. Chamoto, and T. Nishimura, Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells, Biomedical research, vol.30, issue.1, pp.7-15, 2009.

Y. Nefedova, P. Cheng, D. Gilkes, M. Blaskovich, A. A. Beg et al., Activation of dendritic cells via inhibition of Jak2/STAT3 signaling, Journal of immunology, vol.175, issue.7, pp.4338-4384, 2005.

Y. Nefedova, M. Huang, S. Kusmartsev, R. Bhattacharya, P. Cheng et al., Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer, Journal of immunology, vol.172, issue.1, pp.464-74, 2004.

Y. Nie, D. M. Erion, Z. Yuan, M. Dietrich, G. I. Shulman et al., STAT3 inhibition of gluconeogenesis is downregulated by SirT1, Nature cell biology, vol.11, issue.4, pp.492-500, 2009.

C. J. Nirschl and C. G. Drake, Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.19, issue.18, pp.4917-4941, 2013.

H. Nishimura, N. Minato, T. Nakano, and T. Honjo, Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses, International immunology, vol.10, issue.10, pp.1563-72, 1998.

M. Z. Noman, G. Desantis, B. Janji, M. Hasmim, S. Karray et al., , 2014.

, PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSCmediated T cell activation, The Journal of experimental medicine, vol.211, issue.5, pp.781-90

M. Obeid, A. Tesniere, F. Ghiringhelli, G. M. Fimia, L. Apetoh et al., Calreticulin exposure dictates the immunogenicity of cancer cell death, Nature medicine, vol.13, issue.1, pp.54-61, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00451702

H. H. Oberg, M. Peipp, C. Kellner, S. Sebens, S. Krause et al., Novel bispecific antibodies increase gammadelta T-cell cytotoxicity against pancreatic cancer cells, Cancer research, vol.74, issue.5, pp.1349-60, 2014.

A. C. Ochoa, A. H. Zea, C. Hernandez, and P. C. Rodriguez, Arginase, prostaglandins, and myeloidderived suppressor cells in renal cell carcinoma, Cancer Research, vol.13, issue.2, pp.721-726, 2007.

S. Ogino, K. Nosho, N. Irahara, J. A. Meyerhardt, Y. Baba et al., Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.15, issue.20, pp.6412-6432, 2009.

T. Okazaki, S. Chikuma, Y. Iwai, S. Fagarasan, and T. Honjo, A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application, Nature immunology, vol.14, issue.12, pp.1212-1220, 2013.

L. J. Old and E. A. Boyse, Immunology of Experimental Tumors. Annual review of medicine, vol.15, pp.167-86, 1964.

B. Oppmann, R. Lesley, B. Blom, J. C. Timans, Y. Xu et al., Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12, Immunity, vol.13, issue.5, pp.715-740, 2000.

F. Pages, A. Berger, M. Camus, F. Sanchez-cabo, A. Costes et al., Effector memory T cells, early metastasis, and survival in colorectal cancer, The New England journal of medicine, vol.353, issue.25, pp.2654-66, 2005.

A. S. Pak, M. A. Wright, J. P. Matthews, S. L. Collins, G. J. Petruzzelli et al., Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colonystimulating factor, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.1, issue.1, pp.95-103, 1995.

J. Pamment, E. Ramsay, M. Kelleher, D. Dornan, and K. L. Ball, Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway, Oncogene, vol.21, issue.51, pp.7776-85, 2002.

P. Y. Pan, G. X. Wang, B. Yin, J. Ozao, T. Ku et al., Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function, Blood, vol.111, issue.1, pp.219-247, 2008.

T. Panaretakis, O. Kepp, U. Brockmeier, A. Tesniere, A. C. Bjorklund et al., Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death, The EMBO journal, vol.28, issue.5, pp.578-90, 2009.

R. Z. Panni, D. E. Sanford, B. A. Belt, J. B. Mitchem, L. A. Worley et al., Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer, Cancer immunology, immunotherapy : CII, vol.63, issue.5, pp.513-541, 2014.

E. M. Pantelouris, Absence of thymus in a mouse mutant, Nature, vol.217, issue.5126, pp.370-371, 1968.

D. Pardoll, Does the immune system see tumors as foreign or self?, Annual review of immunology, vol.21, pp.807-846, 2003.

J. M. Park, M. Terabe, Y. Sakai, J. Munasinghe, G. Forni et al., Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas, Journal of immunology, vol.174, issue.7, pp.4228-4264, 2005.

A. T. Parsa, J. S. Waldron, A. Panner, C. A. Crane, I. F. Parney et al., Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma, Nature medicine, vol.13, issue.1, pp.84-92, 2007.

S. A. Perez, M. V. Karamouzis, D. V. Skarlos, A. Ardavanis, N. N. Sotiriadou et al., CD4+CD25+ regulatory Tcell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.13, issue.9, pp.2714-2735, 2007.

N. A. Pestov, N. S. Gerasimova, O. I. Kulaeva, and V. M. Studitsky, Structure of transcribed chromatin is a sensor of DNA damage, Science advances, vol.1, issue.6, p.1500021, 2015.

L. W. Pfannenstiel, S. S. Lam, L. A. Emens, E. M. Jaffee, and T. D. Armstrong, Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice, Cellular immunology, vol.263, issue.1, pp.79-87, 2010.

C. Pfirschke, C. Engblom, S. Rickelt, V. Cortez-retamozo, C. Garris et al., , 2016.

, Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy, Immunity, vol.44, issue.2, pp.343-54

J. W. Pollard, Tumour-educated macrophages promote tumour progression and metastasis, Nature reviews Cancer, vol.4, issue.1, pp.71-79, 2004.

I. Poschke, D. Mougiakakos, J. Hansson, G. V. Masucci, and R. Kiessling, Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign, Cancer research, vol.70, issue.11, pp.4335-4380, 2010.

R. Purwar, C. Schlapbach, S. Xiao, H. S. Kang, W. Elyaman et al., Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells, Nature medicine, vol.18, issue.8, pp.1248-53, 2012.

Y. Pylayeva-gupta, K. E. Lee, C. H. Hajdu, G. Miller, and D. Bar-sagi, Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia, Cancer cell, vol.21, issue.6, pp.836-883, 2012.

O. S. Qureshi, Y. Zheng, K. Nakamura, K. Attridge, C. Manzotti et al., Transendocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4, Science, vol.332, issue.6029, pp.600-603, 2011.

P. L. Raber, P. Thevenot, R. Sierra, D. Wyczechowska, D. Halle et al., Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways, International journal of cancer Journal international du cancer, vol.134, issue.12, pp.2853-64, 2014.

L. Raffaghello, C. Lee, F. M. Safdie, M. Wei, F. Madia et al., Starvationdependent differential stress resistance protects normal but not cancer cells against highdose chemotherapy, Proceedings of the National Academy of Sciences of the United States of America, vol.105, issue.24, pp.8215-8235, 2008.

L. Raffaghello, F. Safdie, G. Bianchi, T. Dorff, L. Fontana et al., Fasting and differential chemotherapy protection in patients, Cell cycle, vol.9, issue.22, pp.4474-4480, 2010.

B. Rincon-orozco, V. Kunzmann, P. Wrobel, D. Kabelitz, A. Steinle et al., Activation of V gamma 9V delta 2 T cells by NKG2D, Journal of immunology, vol.175, issue.4, pp.2144-51, 2005.

P. Ritprajak and M. Azuma, Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma, Oral oncology, vol.51, issue.3, pp.221-229, 2015.

N. A. Rizvi, M. D. Hellmann, J. R. Brahmer, R. A. Juergens, H. Borghaei et al., Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for FirstLine Treatment of Advanced Non-Small-Cell Lung Cancer, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.34, issue.25, pp.2969-79, 2016.

N. A. Rizvi, M. D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov et al., Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in nonsmall cell lung cancer, Science, vol.348, pp.124-132, 2015.

C. Robert, L. Thomas, I. Bondarenko, S. O'day, J. Weber et al., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, The New England journal of medicine, vol.364, issue.26, pp.2517-2543, 2011.

L. Robert, J. Tsoi, X. Wang, R. Emerson, B. Homet et al., CTLA4 blockade broadens the peripheral T-cell receptor repertoire, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.20, issue.9, pp.2424-2456, 2014.

F. C. Robertson, J. A. Berzofsky, and M. Terabe, NKT cell networks in the regulation of tumor immunity, Frontiers in immunology, vol.5, p.543, 2014.

P. C. Rodriguez, D. G. Quiceno, and A. C. Ochoa, L-arginine availability regulates T-lymphocyte cell-cycle progression, Blood, vol.109, issue.4, pp.1568-73, 2007.

P. C. Rodriguez, A. H. Zea, K. S. Culotta, J. Zabaleta, J. B. Ochoa et al., Regulation of T cell receptor CD3zeta chain expression by L-arginine, The Journal of biological chemistry, vol.277, issue.24, pp.21123-21132, 2002.

T. Rodriguez, R. Mendez, D. Campo, A. Jimenez, P. Aptsiauri et al., Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lnes, BMC cancer, vol.7, p.34, 2007.

A. Rody, U. Holtrich, L. Pusztai, C. Liedtke, R. Gaetje et al., T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers, Breast cancer research : BCR, vol.11, issue.2, p.15, 2009.

M. S. Rooney, S. A. Shukla, C. J. Wu, G. Getz, and N. Hacohen, Molecular and genetic properties of tumors associated with local immune cytolytic activity, Cell, vol.160, issue.1-2, pp.48-61, 2015.

M. Roselli, V. Cereda, M. G. Di-bari, V. Formica, A. Spila et al., Effects of conventional therapeutic interventions on the number and function of regulatory T cells, Oncoimmunology, vol.2, issue.10, p.27025, 2013.

M. Roselli, V. Formica, V. Cereda, C. Jochems, J. Richards et al., The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy, Oncoimmunology, vol.5, issue.7, p.1188243, 2016.

S. Roth and W. Droge, Regulation of interleukin 2 production, interleukin 2 mRNA expression and intracellular glutathione levels in ex vivo derived T lymphocytes by lactate, European journal of immunology, vol.21, issue.8, pp.1933-1940, 1991.

S. Roth, H. Gmunder, and W. Droge, Regulation of intracellular glutathione levels and lymphocyte functions by lactate, Cellular immunology, vol.136, issue.1, pp.95-104, 1991.

N. Rubinstein, M. Alvarez, N. W. Zwirner, M. A. Toscano, J. M. Ilarregui et al., Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege, Cancer cell, vol.5, issue.3, pp.241-51, 2004.

C. E. Rudd, A. Taylor, and H. Schneider, CD28 and CTLA-4 coreceptor expression and signal transduction, Immunological reviews, vol.229, issue.1, pp.12-26, 2009.

J. Rygaard and C. O. Povlsen, The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance, Acta pathologica et microbiologica Scandinavica Section B: Microbiology and immunology, vol.82, issue.1, pp.99-106, 1974.

S. Sad, R. Marcotte, and T. R. Mosmann, Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines, Immunity, vol.2, issue.3, pp.271-280, 1995.

F. M. Safdie, T. Dorff, D. Quinn, L. Fontana, M. Wei et al., Fasting and cancer treatment in humans: A case series report, Aging, vol.1, issue.12, pp.988-1007, 2009.

A. Saggini, S. Chimenti, and A. Chiricozzi, IL-6 as a druggable target in psoriasis: focus on pustular variants, Journal of immunology research, vol.2014, p.964069, 2014.

K. Sakuishi, L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo et al., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity, The Journal of experimental medicine, vol.207, issue.10, pp.2187-94, 2010.
DOI : 10.1084/jem.201006432011512c
URL : http://jem.rupress.org/content/208/6/1331.full.pdf

K. Sakuishi, P. Jayaraman, S. M. Behar, A. C. Anderson, and V. K. Kuchroo, Emerging Tim-3 functions in antimicrobial and tumor immunity, Trends in immunology, vol.32, issue.8, pp.345-354, 2011.

L. B. Saltz, S. Clarke, E. Diaz-rubio, W. Scheithauer, A. Figer et al., Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.26, issue.12, pp.2013-2022, 2008.

A. Sanchez-fueyo, J. Tian, D. Picarella, C. Domenig, X. X. Zheng et al., Tim-3 inhibits T helper type 1-mediated auto-and alloimmune responses and promotes immunological tolerance, Nature immunology, vol.4, issue.11, pp.1093-101, 2003.

D. Sarhan, F. Cichocki, B. Zhang, A. Yingst, S. R. Spellman et al., Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to MyeloidDerived Suppressor Cells, Cancer research, vol.76, pp.5696-5706, 2016.
DOI : 10.1158/0008-5472.can-16-0839
URL : http://cancerres.aacrjournals.org/content/76/19/5696.full.pdf

P. Scaffidi, T. Misteli, and M. E. Bianchi, Release of chromatin protein HMGB1 by necrotic cells triggers inflammation, Nature, vol.418, issue.6894, pp.191-196, 2002.

P. Schaerli, K. Willimann, A. B. Lang, M. Lipp, P. Loetscher et al., CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function, The Journal of experimental medicine, vol.192, issue.11, pp.1553-62, 2000.

P. H. Schafer, P. Chen, L. Fang, A. Wang, and R. Chopra, The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1), Journal of immunology research, vol.2015, p.906349, 2015.

S. Schenk, C. E. Mccurdy, A. Philp, M. Z. Chen, M. J. Holliday et al., Sirt1 enhances skeletal muscle insulin sensitivity in mice during caloric restriction, The Journal of clinical investigation, vol.121, issue.11, pp.4281-4289, 2011.

B. Schilling, A. Sucker, K. Griewank, F. Zhao, B. Weide et al., Vemurafenib reverses immunosuppression by myeloid derived suppressor cells, International journal of cancer Journal international du cancer, vol.133, issue.7, pp.1653-63, 2013.

M. Schiraldi, A. Raucci, L. M. Munoz, E. Livoti, B. Celona et al., HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4, The Journal of experimental medicine, vol.209, issue.3, pp.551-63, 2012.

S. Schreck, D. Friebel, M. Buettner, L. Distel, G. Grabenbauer et al., Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma, Hematological oncology, vol.27, issue.1, pp.31-40, 2009.

E. I. Sega, D. B. Leveson-gower, M. Florek, D. Schneidawind, R. H. Luong et al., Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation, PloS one, vol.9, issue.1, p.86551, 2014.

L. Senovilla, F. Aranda, L. Galluzzi, and G. Kroemer, Impact of myeloid cells on the efficacy of anticancer chemotherapy, Current opinion in immunology, vol.30, pp.24-31, 2014.

K. S. Sfanos, T. C. Bruno, C. H. Maris, L. Xu, C. J. Thoburn et al., Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.14, issue.11, pp.3254-61, 2008.

V. Shankaran, H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson et al., IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity, Nature, vol.410, issue.6832, pp.1107-1118, 2001.

J. Sheng, W. Fang, J. Yu, N. Chen, J. Zhan et al., Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer, Scientific reports, vol.6, 2016.

L. Z. Shi, R. Wang, G. Huang, P. Vogel, N. G. Green et al., HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells, The Journal of experimental medicine, vol.208, issue.7, pp.1367-76, 2011.

K. Shimizu, M. Hidaka, N. Kadowaki, N. Makita, N. Konishi et al., Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide-loaded murine dendritic cells, Journal of immunology, vol.177, issue.5, pp.3484-92, 2006.

F. Shojaei, X. Wu, C. Zhong, L. Yu, X. H. Liang et al., Bv8 regulates myeloid-celldependent tumour angiogenesis, Nature, vol.450, issue.7171, pp.825-856, 2007.

S. Shu and S. A. Rosenberg, Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells, Journal of immunology, vol.135, issue.4, pp.2895-903, 1985.

M. R. Shurin, Dual role of immunomodulation by anticancer chemotherapy, Nature medicine, vol.19, issue.1, pp.20-22, 2013.

A. Sica and V. Bronte, Altered macrophage differentiation and immune dysfunction in tumor development, The Journal of clinical investigation, vol.117, issue.5, pp.1155-66, 2007.

H. V. Siddle, A. Kreiss, C. Tovar, C. K. Yuen, Y. Cheng et al., Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer, Proceedings of the National Academy of Sciences of the United States of America, vol.110, issue.13, pp.5103-5111, 2013.

E. Simeone, G. Gentilcore, D. Giannarelli, A. M. Grimaldi, C. Caraco et al., Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma, Cancer immunology, immunotherapy : CII, vol.63, issue.7, pp.675-83, 2014.

P. Sinha, C. Okoro, D. Foell, H. H. Freeze, S. Ostrand-rosenberg et al., , 2008.

, Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells, Journal of immunology, vol.181, issue.7, pp.4666-75

V. Sisirak, J. Faget, M. Gobert, N. Goutagny, N. Vey et al., Bendriss-Vermare N (2012) Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression, Cancer research, vol.72, issue.20, pp.5188-97

A. Sistigu, T. Yamazaki, E. Vacchelli, K. Chaba, D. P. Enot et al., Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy, Nature medicine, vol.20, issue.11, pp.1301-1310, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02047408

M. J. Smyth, N. Y. Crowe, D. G. Pellicci, K. Kyparissoudis, J. M. Kelly et al., Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide, Blood, vol.99, issue.4, pp.1259-66, 2002.

M. J. Smyth, M. E. Wallace, S. L. Nutt, H. Yagita, D. I. Godfrey et al., Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer, The Journal of experimental medicine, vol.201, issue.12, pp.1973-85, 2005.

A. Sparmann and D. Bar-sagi, Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis, Cancer cell, vol.6, issue.5, pp.447-58, 2004.

D. R. Spigel, T. J. Ervin, R. A. Ramlau, D. B. Daniel, J. H. Goldschmidt et al., Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.31, issue.32, pp.4105-4119, 2013.

S. Spranger, R. Bao, and T. F. Gajewski, Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity, Nature, vol.523, issue.7559, pp.231-236, 2015.

M. K. Srivastava, P. Sinha, V. K. Clements, P. Rodriguez, and S. Ostrand-rosenberg, Myeloidderived suppressor cells inhibit T-cell activation by depleting cystine and cysteine, Cancer research, vol.70, issue.1, pp.68-77, 2010.

M. Stassen, E. Schmitt, and T. Bopp, From interleukin-9 to T helper 9 cells, Annals of the New York Academy of Sciences, vol.1247, pp.56-68, 2012.

G. Stassi, M. Todaro, M. Zerilli, L. Ricci-vitiani, D. Liberto et al., Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10, Cancer research, vol.63, issue.20, pp.6784-90, 2003.

V. Staudt, E. Bothur, M. Klein, K. Lingnau, S. Reuter et al., Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells, Immunity, vol.33, issue.2, pp.192-202, 2010.

I. M. Stromnes, P. D. Greenberg, and S. R. Hingorani, Clinical cancer research : an official journal of the American Association for, Cancer Research, vol.20, issue.20, pp.5157-70, 2014.

O. Stutman, Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice, Science, vol.183, issue.4124, pp.534-540, 1974.

O. Stutman, Immunodepression and malignancy, Advances in cancer research, vol.22, pp.261-422, 1975.
DOI : 10.1016/s0065-230x(08)60179-7

E. Suzuki, V. Kapoor, A. S. Jassar, L. R. Kaiser, and S. M. Albelda, Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.11, issue.18, pp.6713-6734, 2005.

S. Suzuki, Y. Ichikawa, K. Nakagawa, T. Kumamoto, R. Mori et al., High infiltration of mast cells positive to tryptase predicts worse outcome following resection of colorectal liver metastases, BMC cancer, vol.15, p.840, 2015.

K. Tada, S. Kitano, H. Shoji, T. Nishimura, Y. Shimada et al., Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients, Cancer immunology research, vol.4, issue.7, pp.592-601, 2016.

H. Takahashi, F. Feuerhake, J. L. Kutok, S. Monti, P. Dal-cin et al., FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.12, issue.11, pp.3265-71, 2006.

J. E. Talmadge and D. I. Gabrilovich, History of myeloid-derived suppressor cells, Nature reviews Cancer, vol.13, issue.10, pp.739-52, 2013.

M. L. Tang, M. K. Khan, J. L. Croxford, K. W. Tan, V. Angeli et al., The DNA damage response induces antigen presenting cell-like functions in fibroblasts, European journal of immunology, vol.44, issue.4, pp.1108-1126, 2014.

A. A. Tarhini, H. Edington, L. H. Butterfield, Y. Lin, Y. Shuai et al., Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab, PloS one, vol.9, issue.2, p.87705, 2014.

M. W. Teng, M. D. Vesely, H. Duret, N. Mclaughlin, J. E. Towne et al., Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state, Cancer research, vol.72, issue.16, pp.3987-96, 2012.

W. Y. Teo, M. T. Elghetany, J. Shen, T. K. Man, X. Li et al., Therapeutic implications of CD1d expression and tumorinfiltrating macrophages in pediatric medulloblastomas, Journal of neuro-oncology, vol.120, issue.2, pp.293-301, 2014.

M. Terabe and J. A. Berzofsky, The role of NKT cells in tumor immunity, Advances in cancer research, vol.101, pp.277-348, 2008.

M. Terabe, S. Matsui, J. M. Park, M. Mamura, N. Noben-trauth et al., Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence, The Journal of experimental medicine, vol.198, issue.11, pp.1741-52, 2003.

A. E. Teschendorff, S. Gomez, A. Arenas, D. El-ashry, M. Schmidt et al., Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules, BMC cancer, vol.10, p.604, 2010.

A. Tesniere, F. Schlemmer, V. Boige, O. Kepp, I. Martins et al., Immunogenic death of colon cancer cells treated with oxaliplatin, Oncogene, vol.29, issue.4, pp.482-91, 2010.

M. Thibaudin, M. Chaix, R. Boidot, F. Vegran, V. Derangere et al., Human ectonucleotidase-expressing CD25high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions, Oncoimmunology, vol.5, issue.1, p.1055444, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01438254

M. Tosolini, A. Kirilovsky, B. Mlecnik, T. Fredriksen, S. Mauger et al., Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer, Cancer research, vol.71, issue.4, pp.1263-71, 2011.

I. Traverso, D. Fenoglio, S. Negrini, A. Parodi, F. Battaglia et al., Cyclophosphamide inhibits the generation and function of CD8(+) regulatory T cells, Human immunology, vol.73, issue.3, pp.207-220, 2012.

I. Treilleux, J. Y. Blay, N. Bendriss-vermare, I. Ray-coquard, T. Bachelot et al., Dendritic cell infiltration and prognosis of early stage breast cancer, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.10, issue.22, pp.7466-74, 2004.

F. Triebel, S. Jitsukawa, E. Baixeras, S. Roman-roman, C. Genevee et al., LAG-3, a novel lymphocyte activation gene closely related to CD4, The Journal of experimental medicine, vol.171, issue.5, pp.1393-405, 1990.

G. Trinchieri, S. Pflanz, and R. A. Kastelein, The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses, Immunity, vol.19, issue.5, pp.641-645, 2003.

P. C. Tumeh, C. L. Harview, J. H. Yearley, I. P. Shintaku, E. J. Taylor et al., PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, issue.7528, pp.568-71, 2014.

C. Uyttenhove, L. Pilotte, I. Theate, V. Stroobant, D. Colau et al., Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase, Nature medicine, vol.9, issue.10, pp.1269-74, 2003.

E. Vacchelli, L. Galluzzi, V. Rousseau, A. Rigoni, A. Tesniere et al., Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer, Oncoimmunology, vol.1, issue.3, pp.271-278, 2012.

P. Van-der-bruggen, C. Traversari, P. Chomez, C. Lurquin, E. De-plaen et al., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, vol.254, issue.5038, pp.1643-1650, 1991.

A. Van-elsas, A. A. Hurwitz, and J. P. Allison, Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation, The Journal of experimental medicine, vol.190, issue.3, pp.355-66, 1999.

F. Vegran, H. Berger, R. Boidot, G. Mignot, M. Bruchard et al., The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells, Nature immunology, vol.15, issue.8, pp.758-66, 2014.

M. Veldhoen, C. Uyttenhove, J. Van-snick, H. Helmby, A. Westendorf et al., Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset, Nature immunology, vol.9, issue.12, pp.1341-1347, 2008.

E. J. Villablanca, L. Raccosta, D. Zhou, R. Fontana, D. Maggioni et al., Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses, Nature medicine, vol.16, issue.1, pp.98-105, 2010.

A. V. Villarino, E. Gallo, and A. K. Abbas, STAT1-activating cytokines limit Th17 responses through both T-bet-dependent and -independent mechanisms, Journal of immunology, vol.185, issue.11, pp.6461-71, 2010.

J. Vincent, G. Mignot, F. Chalmin, S. Ladoire, M. Bruchard et al., -Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity, Cancer research, vol.70, issue.8, pp.3052-61, 2010.

T. Voron, O. Colussi, E. Marcheteau, S. Pernot, M. Nizard et al., VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors, The Journal of experimental medicine, vol.212, issue.2, p.272, 2015.

S. Wan, S. Pestka, R. G. Jubin, Y. L. Lyu, Y. C. Tsai et al., Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells, PloS one, vol.7, issue.3, p.32542, 2012.

L. Wang, R. Rubinstein, J. L. Lines, A. Wasiuk, C. Ahonen et al., VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses, The Journal of experimental medicine, vol.208, issue.3, pp.577-92, 2011.

L. Wang, T. Yi, M. Kortylewski, D. M. Pardoll, D. Zeng et al., IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway, The Journal of experimental medicine, vol.206, issue.7, pp.1457-64, 2009.

N. Watanabe, M. Gavrieli, J. R. Sedy, J. Yang, F. Fallarino et al., BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1, Nature immunology, vol.4, issue.7, pp.670-679, 2003.

B. Weide, H. Zelba, E. Derhovanessian, A. Pflugfelder, T. K. Eigentler et al., Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.30, issue.15, pp.1835-1876, 2012.

E. F. Wheelock, Interferon-Like Virus-Inhibitor Induced in Human Leukocytes by Phytohemagglutinin, Science, vol.149, issue.3681, pp.310-311, 1965.

S. R. Woo, N. Li, T. C. Bruno, K. Forbes, S. Brown et al., Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4, European journal of immunology, vol.40, issue.6, pp.1768-77, 2010.

S. R. Woo, M. E. Turnis, M. V. Goldberg, J. Bankoti, M. Selby et al., Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape, Cancer research, vol.72, issue.4, pp.917-944, 2012.

C. J. Workman, K. J. Dugger, and D. A. Vignali, Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3, Journal of immunology, vol.169, issue.10, pp.5392-5397, 2002.

S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell, Transforming growth factor-beta and the immune response: implications for anticancer therapy, Cancer Research, vol.13, pp.5262-70, 2007.

C. Wu, N. Yosef, T. Thalhamer, C. Zhu, S. Xiao et al., Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1, Nature, vol.496, issue.7446, pp.513-520, 2013.

X. Wu, M. Peng, B. Huang, H. Zhang, H. Wang et al., Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma, Cancer letters, vol.340, issue.1, pp.124-157, 2013.

L. Yang, L. M. Debusk, K. Fukuda, B. Fingleton, B. Green-jarvis et al., Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis, Cancer cell, vol.6, issue.4, pp.409-430, 2004.

L. Yang, Y. Pang, and H. L. Moses, TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression, Trends in immunology, vol.31, issue.6, pp.220-227, 2010.

X. O. Yang, B. P. Pappu, R. Nurieva, A. Akimzhanov, H. S. Kang et al., T helper 17 lineage 273 differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma, Immunity, vol.28, issue.1, pp.29-39, 2008.

X. P. Yang, K. Ghoreschi, S. M. Steward-tharp, J. Rodriguez-canales, J. Zhu et al., Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5, Nature immunology, vol.12, issue.3, pp.247-54, 2011.

N. K. Yoon, E. L. Maresh, D. Shen, Y. Elshimali, S. Apple et al., Higher levels of GATA3 predict better survival in women with breast cancer, Human pathology, vol.41, issue.12, pp.1794-801, 2010.

J. I. Youn, S. Nagaraj, M. Collazo, and D. I. Gabrilovich, Subsets of myeloid-derived suppressor cells in tumor-bearing mice, Journal of immunology, vol.181, issue.8, pp.5791-802, 2008.

M. R. Young, M. Newby, and H. T. Wepsic, Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors, Cancer research, vol.47, issue.1, pp.100-105, 1987.

M. R. Young and M. A. Wright, Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: gamma interferon plus tumor necrosis factor alpha synergistically reduces immune suppressor and tumor growth-promoting activities of bone marrow cells and diminishes tumor recurrence and metastasis, Cancer research, vol.52, issue.22, pp.6335-6375, 1992.

H. Yu, M. Kortylewski, and D. Pardoll, Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment, Nature reviews Immunology, vol.7, issue.1, pp.41-51, 2007.

X. Yu, K. Harden, L. C. Gonzalez, M. Francesco, E. Chiang et al., The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells, Nature immunology, vol.10, issue.1, pp.48-57, 2009.

J. Yuan, S. Gnjatic, H. Li, S. Powel, H. F. Gallardo et al., CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit, Proceedings of the National Academy of Sciences of the United States of America, vol.105, issue.51, pp.20410-20415, 2008.

Z. L. Yuan, Y. J. Guan, D. Chatterjee, and Y. E. Chin, Stat3 dimerization regulated by reversible acetlation of a single lysine residue, Science, vol.307, issue.5707, pp.269-73, 2005.

B. Zhang, Z. Wang, L. Wu, M. Zhang, W. Li et al., Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma, PloS one, vol.8, issue.2, p.57114, 2013.

J. P. Zhang, J. Yan, J. Xu, X. H. Pang, M. S. Chen et al., Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients, Journal of hepatology, vol.50, issue.5, pp.980-989, 2009.

Q. Zhang, M. Raoof, Y. Chen, Y. Sumi, T. Sursal et al., Circulating mitochondrial DAMPs cause inflammatory responses to injury, Nature, vol.464, issue.7285, pp.104-111, 2010.

Z. J. Zhang, Z. J. Zheng, H. Kan, Y. Song, W. Cui et al., Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis, Diabetes care, vol.34, issue.10, p.274, 2011.

S. G. Zheng, J. H. Wang, W. Stohl, K. S. Kim, J. D. Gray et al., TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells, Journal of immunology, vol.176, issue.6, pp.3321-3330, 2006.

W. Zou, V. Machelon, A. Coulomb-l'hermin, J. Borvak, F. Nome et al., Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells, Nature medicine, vol.7, issue.12, pp.1339-1385, 2001.